Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Mallinckrodt plc | mnkexhibit991q42017er.htm |
| 8-K - 8-K 2.27.2018 - Mallinckrodt plc | mnk8-k022718.htm |
Exhibit 99.2
On February 22, 2018, the Company’s Board of Directors authorized commencement of a process to dispose of (1) the Company’s Specialty Generics business comprised of its Specialty Generics segment, with the exception of its external manufacturing operations, (2) certain of the Company’s non-promoted brands business, which is currently reflected in the Specialty Brands segment; and (3) the Company's ongoing, post-divestiture supply agreement with the acquirer of the CMDS business, which is currently reflected in the Other non-operating segment (referred to collectively as the “Specialty Generics Disposal Group”). Beginning in the first quarter of fiscal 2018, the historical financial results attributable to the Specialty Generics Disposal Group will be reflected in the Company’s consolidated financial statements as discontinued operations. Below is the Company's select product line net sales of the continuing operations following the classification of the disposal group above into discontinued operations for the respective periods.
MALLINCKRODT PLC | |||||||||||||||||||
SELECT PRODUCT LINE NET SALES | |||||||||||||||||||
(unaudited, in millions) | |||||||||||||||||||
Three Months Ended | Fiscal Year Ended | ||||||||||||||||||
March 31, 2017 | June 30, 2017 | September 29, 2017 | December 29, 2017 | December 29, 2017 | |||||||||||||||
H.P. Acthar Gel | $ | 271.8 | $ | 319.4 | $ | 308.7 | $ | 295.2 | $ | 1,195.1 | |||||||||
Inomax | 128.4 | 125.5 | 125.7 | 125.6 | 505.2 | ||||||||||||||
Ofirmev | 73.4 | 75.7 | 75.4 | 78.0 | 302.5 | ||||||||||||||
Therakos | 51.2 | 51.2 | 55.3 | 57.2 | 214.9 | ||||||||||||||
BioVectra | 9.9 | 10.5 | 16.0 | 18.3 | 54.7 | ||||||||||||||
Other (1) | 25.3 | 17.8 | 19.5 | 17.2 | 79.8 | ||||||||||||||
Specialty Brands Total | $ | 560.0 | $ | 600.1 | $ | 600.6 | $ | 591.5 | $ | 2,352.2 | |||||||||
Three Months Ended | |||||||||||||||||||
December 30, 2016 | |||||||||||||||||||
H.P. Acthar Gel | 325.4 | ||||||||||||||||||
Inomax | 118.3 | ||||||||||||||||||
Ofirmev | 72.5 | ||||||||||||||||||
Therakos | 47.4 | ||||||||||||||||||
BioVectra | 7.4 | ||||||||||||||||||
Other (1) | 29.4 | ||||||||||||||||||
Specialty Brands Total | $ | 600.4 | |||||||||||||||||
Three Months Ended | Fiscal Year Ended | ||||||||||||||||||
December 25, 2015 | March 25, 2016 | June 24, 2016 | September 30, 2016 | September 30, 2016 | |||||||||||||||
H.P. Acthar Gel | $ | 286.7 | $ | 248.4 | $ | 298.3 | $ | 327.0 | $ | 1,160.4 | |||||||||
Inomax | 110.8 | 115.5 | 121.1 | 126.9 | 474.3 | ||||||||||||||
Ofirmev | 66.9 | 71.1 | 70.7 | 75.6 | 284.3 | ||||||||||||||
Therakos | 50.4 | 50.2 | 52.5 | 54.5 | 207.6 | ||||||||||||||
BioVectra | 14.2 | 13.0 | 9.0 | 13.3 | 49.5 | ||||||||||||||
Other (1) | 16.4 | 29.0 | 34.4 | 36.0 | 115.8 | ||||||||||||||
Specialty Brands Total | $ | 545.4 | $ | 527.2 | $ | 586.0 | $ | 633.3 | $ | 2,291.9 | |||||||||
(1) Includes the historical net sales of the completed Intrathecal therapy divestiture and the planned Hemostasis products divestiture, both of which do not qualify for discontinued operations classification under U.S. GAAP.